- Report
- April 2026
- 157 Pages
Global
From €3649EUR$3,950USD£3,057GBP
- Report
- April 2026
- 154 Pages
Global
From €3649EUR$3,950USD£3,057GBP
- Report
- January 2026
- 150 Pages
Global
From €3649EUR$3,950USD£3,057GBP
- Report
- January 2026
- 149 Pages
Global
From €3649EUR$3,950USD£3,057GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- July 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- July 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- July 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- April 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- February 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- January 2026
- 160 Pages
Global
From €2920EUR$3,160USD£2,445GBP
€3649EUR$3,950USD£3,057GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP
- Report
- August 2026
- 160 Pages
Global
From €3067EUR$3,320USD£2,569GBP
€3834EUR$4,150USD£3,212GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more